Evidence map›Paper›PMID 41974533›Full record

ReviewKorean journal of radiology2026

Breast Cancer Screening Programs in China: Implementation, Challenges, and Future Perspectives.

Hongping Song, Woo Kyung Moon

Abstract readReview
In one paragraph

Review in Korean journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hongping SongDepartment of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, China. song.hp@foxmail.com.ORCID https://orcid.org/0000-0001-8764-4199
Woo Kyung MoonDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-8931-3772

Funding

Innovative Medical Research Special Project of Xijing Hospital Boosting Program XJZT25CX03National Natural Science Foundation of China 82071934National Natural Science Foundation of China 82471991
6 · The paper itself

Abstract

According to GLOBOCAN 2022, China accounts for the highest number of new breast cancer cases and the second highest number of breast cancer deaths globally. As part of the national public health initiative, a population-based breast cancer screening program was launched in 2009, initially targeting rural women and later expanded to include rural and urban women aged 35-64 years from 2019 onwards. The screening approach in China relies on ultrasonography (US) and mammography. Although mammography is an evidence-based standard, US plays a major role due to limited mammography resources and a high prevalence of dense breasts. Understanding the real-world implementation of breast cancer screening programs in China may provide valuable insights for breast cancer screening practices in other countries. This review summarizes the implementation and achievements of China's breast cancer screening programs, evaluates the role of US within the current screening framework, and discusses the key challenges and future directions.

Indexed as

Breast NeoplasmsEarly Detection of CancerMammographyMass ScreeningUltrasonography, MammaryChinaFemaleHumansMiddle AgedBreast cancerChinaMammographyScreeningUltrasound

Identifiers

PMID41974533
PMCPMC13136581

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.